Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496780 · ClinicalTrials.gov registry record · Phase 2
The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02496780 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 65 participants.
The verdict
NCT02496780, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
Insulin replacement therapy may be effective in breaking the cycle of protein catabolism, undernutrition and overall clinical deterioration in pre-diabetic, insulin insufficient CF youth because of its potent anabolic effect. A significant number of CF patients might benefit from this therapeutic approach with a substantial impact on morbidity and mortality.
Interventions
- DRUG placebo
- DRUG novolog insulin
- DRUG levemir insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-08 |
| Est. Completion | 2022-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496780
The ClinicalTrials.gov registry entry for NCT02496780 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02496780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02496780 about?
NCT02496780 is a clinical study titled "The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients". Insulin replacement therapy may be effective in breaking the cycle of protein catabolism, undernutrition and overall clinical deterioration in pre-diabetic, insulin insufficient CF youth because of its potent anabolic effect. A significant number of CF patients might benefit from this therapeutic ap...
What is the current status of trial NCT02496780?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2015-08. Estimated completion is 2022-07.
What interventions are being tested in trial NCT02496780?
The interventions under investigation include: placebo (DRUG), novolog insulin (DRUG), levemir insulin (DRUG).
Who is sponsoring clinical trial NCT02496780?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.